Phase I study of MCLA-145, a bispecific antibody targeting CD137 and PD-L1, in solid tumors, as monotherapy or in combination with pembrolizumab

被引：0
|
作者：
Kyi, Chrisann
Van Dongen, Marloes
Rottey, Sylvie
Bermejo, Ignacio Melero
Mittag, Diana
Gouveia, Dane
Bol, Kees
Yan, Chris
Joe, Andrew K.
Laus, Gianluca
Moreno, Victor
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Netherlands Canc Inst, Antoni Van Leeuwenhoek, Amsterdam, Netherlands
[3] Ghent Univ Hosp, Ghent, Belgium
[4] Univ Navarra Clin, Pamplona, Spain
[5] Merus NV, Utrecht, Netherlands
[6] Univ Hosp Fdn Jimenez Diaz, START Madrid FJD, Madrid, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2520
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A Phase I/Il Study of MCLA-128, a full length IgG1 Bispecific Antibody Targeting HER2 and HER3 in Patients with Solid Tumors
    Calvo, Emiliano
    Alsina, Maria
    Schellens, Jan H. M.
    Huitema, Alwin D. R.
    Tabernero, Josep
    de Vries-Schultink, Aurelia
    Boni, Valentina
    Doger, Bernard
    Geuijen, Cecile
    Doornbos, Robert
    Bol, Kees
    Westendorp, Martine
    Throsby, Mark
    Bakker, Lex
    Shamsili, Setareh
    CANCER RESEARCH, 2016, 76
  • [42] IOH-001, a novel CD47/PD-L1 bispecific antibody, enhances anti-tumor activity in solid tumors
    Kim, Jeong-kook
    Jeon, A-Ra
    Park, Jihyun
    Choi, Ji Yea
    Park, Ji Eun
    Song, Sun Kwang
    Choi, Ji Hye
    Shin, Heewook
    Lee, Ji Hye
    Yun, Ji Hye
    Ahn, Yoen Hee
    Kim, Heung Tae
    CANCER RESEARCH, 2022, 82 (12)
  • [43] Development of a Bispecific Antibody 124I-NB12 for Imaging PD-L1/2 Expression in Tumors
    Yao, Y.
    Li, N.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S189 - S189
  • [44] Intravenous administration of ALKS 4230 as monotherapy and in combination with pembrolizumab in a phase I study of patients with advanced solid tumors.
    Vaishampayan, Ulka N.
    Fishman, Mayer N.
    Cho, Daniel C.
    Hoimes, Christopher J.
    Velcheti, Vamsidhar
    McDermott, David F.
    Slichenmyer, William J.
    Putiri, Emily
    Losey, Heather
    Rossi, Sean
    Ernstoff, Marc S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [45] A phase I/Ib study of MPT-0118 as monotherapy and in combination with pembrolizumab in subjects with advanced or metastatic solid tumors
    Sommerhalder, D.
    Lim, E. A.
    Pande, A.
    Keller, P.
    ANNALS OF ONCOLOGY, 2021, 32 : S866 - S866
  • [46] A phase 1, dose escalation/dose-expansion study of QLF31907, a bispecific antibody (BsAb) targeting PD-L1 and 4-1BB, in patients with advanced solid tumors and lymphoma
    Lin, Tongyu
    Liu, Bin
    Pu, Xingxiang
    Wu, Lin
    Du, Xiaobo
    Mo, Ning
    Song, Zhengbo
    Zhou, Liwei
    Duan, Xianlin
    Zhu, Yanan
    Kang, Xiaoyan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [47] The first-in-class bispecific antibody IBI318 (LY3434172) targeting PD-1 and PD-L1 in patients with advanced tumors: a phase Ia/Ib study
    Ruan, Dan-Yun
    Wei, Xiao-Li
    Liu, Fu-Rong
    Hu, Xi-Chun
    Zhang, Jian
    Ji, Dong-Mei
    Huang, Ding-Zhi
    Zhao, Yan-Qiu
    Pan, Hong-Min
    Liao, Wang-Jun
    Yang, Kun-Yu
    Xu, Nong
    Lu, Xiao-Xiao
    Chen, Yu-Ling
    Zhang, Wen
    Zhou, Hui
    Zhao, Hong-Yun
    Xu, Rui-Hua
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2024, 17 (01)
  • [48] A phase 1 study of MEDI4736, an anti PD-L1 antibody, in patients with advanced solid tumors.
    Lutzky, Jose
    Antonia, Scott Joseph
    Blake-Haskins, Andy
    Li, Xia
    Robbins, Paul B.
    Shaiabl, Aiman M.
    Vasseill, Jim
    Ibrahim, Ramy A.
    Khleif, Samir
    Segal, Neil Howard
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [49] Phase 1/2a clinical trial of BI-1206, an anti-CD32b (FcgRIIB) antibody, in combination with pembrolizumab in subjects with advanced solid tumors previously treated with anti-PD-1/PD-L1
    Carneiro, Ana
    Yachnin, Jeffrey
    Aljumaily, Raid
    Abel, Edvard
    Falchook, Gerald Steven
    Ji, Yan
    Borggren, Marie
    Martensson, Linda
    Gertsson, Susanne
    Karlsson, Ingrid
    Teige, Ingrid
    Tehranchi, Ramin
    Wallin, Johan Erik
    Chisamore, Michael Jon
    Frendeus, Bjorn
    McAllister, Andres
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [50] Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2)
    Davar, Diwakar
    Cavalcante, Ludimila
    Lakhani, Nehal
    Moser, Justin
    Millward, Michael
    Mckean, Meredith
    Voskoboynik, Mark
    Sanborn, Rachel E.
    Grewal, Jaspreet S.
    Narayan, Ajita
    Patnaik, Amita
    Gainor, Justin F.
    Sznol, Mario
    Enstrom, Amanda
    Blanchfield, Lori
    Leblanc, Heidi
    Thomas, Heather
    Chisamore, Michael J.
    Peng, Stanford L.
    Naumovski, Allison
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (08)
12345